Judge James C. Mahan of the US District Court denied the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization (BIO)’s motion for a temporary restraining order that would force Nevada to “cease and desist all action implementing or enforcing” contested sections of Nevada’s Senate Bill 539.
Judge James C. Mahan of the US District Court denied the Pharmaceutical Research and Manufacturers of America (PhRMA) and Biotechnology Innovation Organization (BIO)’s motion for a temporary restraining order that would force Nevada to “cease and desist all action implementing or enforcing” contested sections of Nevada’s Senate Bill (SB) 539.
SB 539, signed into law by Republican Governor Brian Sandoval, requires drug makers to annually disclose list prices for insulins, profits made, and discounts provided to pharmacy benefit managers. It also requires drug makers to explain spikes in insulin pricing. Trade groups PhRMA and BIO called the drug “unprecedented” and “unconstitutional.”
In his decision, Mahan indicated that the court could rule a temporary restraining order only if the moving party showed that immediate and irreparable loss or damage would result before the opposing party’s motion for a preliminary injunction could be heard. He called such a restraining order an “extraordinary remedy” that would not be granted without the plaintiff’s demonstrating the possibility of irreparable. Mahan said that PhRMA and BIO had not shown that they would suffer such damage, in part because the first disclosures from industry concerning drug pricing will not be due until July of 2018.
Now that the motion for the restraining order has been denied, the state will have until September 27, 2017 to file its reply to PhRMA and BIO’s motion for preliminary injunction.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.